We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Liquid Nanolaser Technology May Be Used for Lab-on-a-Chip Diagnostic Applications

By LabMedica International staff writers
Posted on 07 Jul 2015
Improvements in nanoscale laser technology enable biotechnology researchers to envisage the use of such a device as the focal point for "lab on a chip" diagnostic applications.

Investigators at Northwestern University (Evanston, IL, USA) described an approach to achieve real-time, tunable lattice plasmon laser capability in the April 20, 2015, online edition of the journal Nature Communications. Their tunable liquid-based laser was constructed from arrays of gold nanoparticles and liquid gain materials.

Optically pumped arrays of gold nanoparticles surrounded by liquid dye molecules exhibited lasing emission that could be tuned as a function of the dielectric environment. More...
Wavelength-dependent time-resolved experiments showed distinct lifetime characteristics below and above the lasing threshold. By integrating gold nanoparticle arrays within microfluidic channels and flowing in liquid gain materials with different refractive indices, the investigators achieved dynamic tuning of the plasmon lasing wavelength.

Nanoscale lasers can be mass-produced with emission wavelengths over the entire gain bandwidth of the dye employed. Thus, the same gold nanoparticle array can exhibit lasing wavelengths that can be tuned over 50 nanometers, from 860 to 910 nanometers, simply by changing the solvent used to dissolve the dye.

“Our study allows us to think about new laser designs and what could be possible if they could actually be made,” said Dr. Teri W. Odom, professor of chemistry at Northwestern University. “My lab likes to go after new materials, new structures, and new ways of putting them together to achieve things not yet imagined. We believe this work represents a conceptual and practical engineering advance for on-demand, reversible control of light from nanoscopic sources.”

Related Links:

Northwestern University



New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Clinical Informatics Platform
CLARION™
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.